Notícias

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.

Eli Lilly’s investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.

Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.

By Sriparna Roy May 21 (Reuters) - Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's

Demand for weight loss drugs may fuel growth for more than one player.

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO David Ricks told investors “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue ... Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

LONDON/NEW YORK, May 21 (Reuters) - Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U. Prices for the lowest doses of both Novo's oral Wegovy and Lilly's Foundayo tend to be lower than for their injected obesity ‌medicines, and at par with those offered by pharmacies that mix the ingredients themselves and make compounded versions.

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Novo Nordisk-linked pharmaceutical strength helped Denmark post a fourth straight quarter of economic expansion.

Earlier in May 2026, Novo Nordisk presented new sub-analyses from its OASIS 4 and STEP UP phase 3 trials at the European Congress on Obesity, showing strong weight-loss efficacy, improved physical function and favourable body composition effects for both oral and injectable Wegovy across diverse adult and female patient groups. The company also reported that Wegovy’s oral pill compared favourably with rival orforglipron on weight loss, tolerability and patient preference, reinforcing...

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.

Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.

Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.

(Updates with Novo Nordisk's response in the fourth and fifth paragraphs.) The US Supreme Court o

Novo Nordisk (CPSE:NOVO B) is transferring its clinical-stage Parkinson's cell therapy program, including global rights, to Cellular Intelligence. As part of the deal, Novo Nordisk will take an equity stake in Cellular Intelligence and remain eligible for milestones and royalties linked to the therapy. The program holds fast track designation for Parkinson's disease and aims to use AI-supported manufacturing and clinical optimization to accelerate development timelines. Novo Nordisk, best...

This dark horse in the weight loss drug race is worth keeping on your watch list.

The company is riding an incredible tailwind.

Eli Lilly (NYSE:LLY) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion. But here’s what you should actually be watching. The ... Three Biotechs That Are Top Takeover Targets

These stocks could look like steals in a few years.

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning tradi

Baxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.

Drugmaker sees international markets as next test for obesity pill demand.

Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy...

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

Recent performance snapshot for Novo Nordisk (NVO) With no single headline event driving the move, Novo Nordisk (NVO) has drawn attention after a mixed stretch for the stock, including a gain of about 10% over the past month alongside weaker longer term returns. See our latest analysis for Novo Nordisk. Recent trading paints a mixed picture, with the share price up about 10% over the past month yet down over longer horizons, including a year to date decline of 14.6% and a 1 year total...

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

There's a new challenger to the more established players in the weight-loss drug space.